Early menopause in long-term survivors of cancer during adolescence

Byrne, Jennifer; Fears, TR; Gail, MH; Pee, David; Connelly, Roger R.; Df, Austin; Holmes, GF; Ff, Holmes; Hb, Latourette; Meigs, J. Wister; Lc, Strong; Myers, MH; Mulvihill, JJ

doi:10.1016/0020-7292(92)90686-d

Cited by 48 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is probably caused by radiation-induced changes in the myometrium or uterine vasculature [9,20]. If gonadal function is preserved or recovers, however, patients are still at risk for early menopause [5], as is shown by the girl who had a spontaneous onset of puberty and menarche but later developed secondary amenorrhoea and hypogonadism. As recovery of ovarian function after hypergonadotrophic hypogonadism is possible, hormonal substitution should be stopped at regular intervals in order to re-evaluate gonadal function.…”

Section: Discussionmentioning

confidence: 99%

Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies

Bakker¹,

Massa

Oostdijk³

et al. 2000

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies

Bakker¹,

Massa

Oostdijk³

et al. 2000

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…In addition, women who maintain normal menses throughout chemotherapy remain at risk for the development of early menopause. A study of cancer survivors treated between the ages of 13 and 19 years with alkylating agentbased chemotherapy in the absence of radiotherapy found the patients to have an increased relative risk of 9.2 over control subjects of developing premature menopause [15]. The high rates of premature ovarian failure observed in adolescents receiving alkylating agents suggest that women of all ages are at risk for chemotherapy-related gonadal toxicity following alkylating agent-containing adjuvant chemotherapy for breast cancer.…”

Section: Chemotherapymentioning

confidence: 98%

Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer

Moore

2000

Curr Oncol Rep

View full text Add to dashboard Cite

Issues of long-term toxicity from treatment for breast cancer, including the induction of premature ovarian failure, appear to be of increasing importance for breast cancer survivors. The incidence of treatment-related amenorrhea is related to patient age and to the treatment regimen. Whereas the induction of ovarian failure may be advantageous with respect to breast cancer outcome, it is not clear that there is any advantage to permanent menopause over reversible hormonal manipulations. In addition, menopause may be associated with a variety of adverse health effects. Although nonhormonal therapies are available to manage many of the consequences of menopause, avoidance of chemotherapy-related ovarian toxicity may provide the best prospects for fertility after treatment. Pregnancy after breast cancer is a realistic consideration for some breast cancer survivors and is not clearly detrimental to either the mother or her offspring.

show abstract

“…Younger patients often continue with normal ovarian function after cytotoxic insult, but they may undergo premature menopause. Byrne et al [64] took menstrual histories from over 1000 women who were still menstruating at the age of 21 after receiving treatment for malignancy during childhood. They found a much higher rate of premature menopause in these women compared with a control population, with 42% of the treated women having reached menopause by the age of 31, compared with only 5% of the control subjects.…”

Section: Chemotherapymentioning

confidence: 99%

Fertility preservation and management of gonadal failure associated with lymphoma therapy

Howell¹,

Shalet

2002

Curr Oncol Rep

View full text Add to dashboard Cite

Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, either directly or indirectly, is also a significant cause of gonadal dysfunction, and the potential to recover from damage is clearly related to the radiation dose received. Several methods of preserving gonadal function during potentially sterilizing treatment have been considered. At present, sperm banking remains the only proven method in men, although hormonal manipulation to enhance recovery of spermatogenesis and cryopreservation of testicular germ cells are possibilities for the future. Transposition of the ovaries to allow better shielding during radiotherapy is of use in some women, and the prospect of cryopreservation and reimplanation of ovarian tissue appears to be promising.

show abstract

Early menopause in long-term survivors of cancer during adolescence

Cited by 48 publications

References 0 publications

Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies

Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies

Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer

Fertility preservation and management of gonadal failure associated with lymphoma therapy

Contact Info

Product

Resources

About